A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
CJ-023,423 is a new medication being developed as an anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to evaluate whether patients treated with CJ-023,423 for 7 days (14 doses) have fewer gastrointestinal ulcers compared to patients treated with naproxen and placebo.
Epistemonikos ID: 92fb01d6351a67fb5aa99703830fa6adcea628aa
First added on: May 04, 2024